Does Medicare Cover Ovarian Cancer Treatment — Complete Guide 2026
Does Medicare cover ovarian cancer treatment in 2026? Ovarian cancer is the fifth leading cause of cancer death among women in the United States — with approximately 20,000 new cases diagnosed annually and the majority occurring in postmenopausal women over 60. Ovarian cancer is often called the silent killer because it is frequently diagnosed at an advanced stage when treatment is more complex. The good news is that yes — does Medicare cover ovarian cancer treatment in 2026 — comprehensively across all stages including surgery, chemotherapy, targeted therapy, PARP inhibitors, and bevacizumab. In this complete guide we explain exactly what Medicare covers for ovarian cancer treatment in 2026. All information is sourced from Medicare.gov and CMS.gov.
Also Read —
- Does Medicare Cover Cancer Treatment 2026
- Does Medicare Cover Breast Cancer Treatment 2026
- Medicare Part B vs Part D Drug Coverage 2026
What You Will Learn — Does Medicare Cover Ovarian Cancer
- Does Medicare cover ovarian cancer treatment in 2026
- Does Medicare cover ovarian cancer surgery
- Does Medicare cover chemotherapy for ovarian cancer
- Does Medicare cover PARP inhibitors — Lynparza Zejula Rubraca
- Does Medicare cover bevacizumab for ovarian cancer
- Does Medicare cover CA-125 testing
- Does Medicare cover BRCA testing for ovarian cancer
- How much does ovarian cancer treatment cost with Medicare
- Does Medicare Advantage cover ovarian cancer
- Frequently asked questions about Medicare ovarian cancer coverage 2026
Does Medicare Cover Ovarian Cancer Treatment in 2026?
Yes — does Medicare cover ovarian cancer treatment in 2026 — comprehensively across all stages and treatment modalities. Medicare Part B covers gynecologic oncology visits, diagnostic imaging, ovarian cancer surgery including debulking procedures, IV chemotherapy, and bevacizumab infusions. Medicare Part D covers oral PARP inhibitors including olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). Medicare Part B also covers IP (intraperitoneal) chemotherapy administration which is used in some ovarian cancer protocols.
Ovarian cancer treatment typically involves a combination of surgery and chemotherapy — with surgery aiming to remove as much cancer as possible (cytoreduction or debulking) followed by platinum-based chemotherapy. In recent years PARP inhibitors have transformed maintenance therapy for ovarian cancer — particularly for patients with BRCA mutations — and Medicare’s coverage of these expensive oral agents through Part D with the $2,000 annual maximum is critically important for ovarian cancer patients.
Does Medicare Cover Ovarian Cancer Diagnosis?
Does Medicare cover diagnostic workup for ovarian cancer in 2026? Yes — Medicare Part B covers all major diagnostic procedures for ovarian cancer at 80% after the $257 annual Part B deductible.
Pelvic Ultrasound — Covered
Transvaginal and transabdominal ultrasound for evaluating ovarian masses — covered at 80% after deductible.
CT Scan — Covered
CT scan of abdomen and pelvis for staging ovarian cancer — covered at 80%.
PET Scan — Covered
PET scan for evaluating metastatic disease — covered at 80% after deductible.
MRI — Covered
MRI pelvis for detailed evaluation of pelvic masses — covered at 80%.
CA-125 Blood Test — Covered at $0
CA-125 — the primary tumor marker for ovarian cancer — is covered as a diagnostic laboratory test at $0 when medically ordered. CA-125 is used for:
- Initial diagnosis workup
- Monitoring treatment response
- Surveillance after treatment to detect recurrence
The $0 CA-125 coverage is particularly valuable for ovarian cancer survivors requiring regular monitoring — typically every 3 months during active surveillance.
HE4 — Covered at $0
HE4 — human epididymis protein 4 — another ovarian cancer biomarker — covered at $0 as diagnostic laboratory.
ROMA Score — Covered
Risk of Ovarian Malignancy Algorithm combining CA-125 and HE4 — covered.
Does Medicare Cover BRCA Testing for Ovarian Cancer?
Does Medicare cover BRCA genetic testing for ovarian cancer in 2026? Yes — Medicare covers BRCA1 and BRCA2 mutation testing for qualifying patients.
BRCA Testing Coverage
Medicare Part B covers BRCA genetic testing for:
- Women diagnosed with ovarian cancer — BRCA status guides PARP inhibitor selection and maintenance therapy decisions
- Women with a family history of BRCA-related cancers — covered as genetic counseling and testing
BRCA testing is covered at 80% after the deductible when ordered by a physician. Given that BRCA status directly determines eligibility for FDA-approved PARP inhibitor maintenance therapy this testing is critically important for ovarian cancer patients.
Does Medicare Cover Ovarian Cancer Surgery?
Does Medicare cover ovarian cancer surgery in 2026? Yes — Medicare covers all major ovarian cancer surgical procedures.
Primary Debulking Surgery — Covered
Primary cytoreductive surgery — the cornerstone of ovarian cancer treatment — removing as much tumor as possible including the ovaries, fallopian tubes, uterus, omentum, and any other involved tissue — covered under Medicare Part A for inpatient procedures.
Interval Debulking Surgery — Covered
Debulking surgery performed after neoadjuvant chemotherapy — covered.
Secondary Cytoreduction — Covered
Surgery for recurrent ovarian cancer — covered.
Staging Surgery — Covered
Surgical staging for early ovarian cancer — covered.
Surgical Costs with Medicare
Major gynecologic oncology surgery inpatient:
- Part A deductible — $1,676 per benefit period
- Days 1 to 60 — $0 after deductible
- Surgeon fee — 20% Part B coinsurance
With Medigap Plan G — ovarian cancer surgery costs $0 after the $257 annual Part B deductible — covering both the $1,676 Part A deductible and all surgeon coinsurance.
Does Medicare Cover Chemotherapy for Ovarian Cancer?
Does Medicare cover chemotherapy for ovarian cancer in 2026? Yes — Medicare covers all major chemotherapy regimens for ovarian cancer.
IV Chemotherapy — Part B
Standard first-line ovarian cancer chemotherapy — covered under Medicare Part B at 80% after the deductible:
- Carboplatin — covered Part B — platinum agent — backbone of ovarian cancer treatment
- Paclitaxel (Taxol) — covered Part B — taxane — standard combination with carboplatin
- Docetaxel — covered Part B — alternative taxane
- Cisplatin — covered Part B
- Gemcitabine — covered Part B — used in recurrent ovarian cancer
- Pegylated liposomal doxorubicin (Doxil) — covered Part B — for recurrent disease
- Topotecan — covered Part B — for recurrent platinum-resistant disease
- Etoposide — covered Part B
Intraperitoneal Chemotherapy — Covered
IP chemotherapy — delivering chemotherapy directly into the peritoneal cavity through a port — is covered by Medicare for appropriate ovarian cancer patients. Both the chemotherapy drugs and the IP administration are covered at 80% after deductible.
Neoadjuvant Chemotherapy — Covered
Pre-surgical chemotherapy for advanced ovarian cancer — carboplatin and paclitaxel before interval debulking — covered at 80%.
With Medigap Plan G — all IV chemotherapy costs $0 after the annual deductible — one of the most important financial protections for ovarian cancer patients undergoing multi-cycle chemotherapy.
Does Medicare Cover Bevacizumab for Ovarian Cancer?
Does Medicare cover bevacizumab for ovarian cancer in 2026? Yes — Medicare Part B covers bevacizumab (Avastin) for ovarian cancer at 80% after the $257 annual Part B deductible.
Bevacizumab Coverage for Ovarian Cancer
Bevacizumab is FDA-approved and widely used for ovarian cancer in multiple settings:
- First-line treatment combined with carboplatin and paclitaxel followed by bevacizumab maintenance
- Platinum-sensitive recurrent ovarian cancer in combination with chemotherapy
- Platinum-resistant recurrent ovarian cancer in combination with paclitaxel or topotecan
Bevacizumab Cost with Medicare
Bevacizumab infusions every 3 weeks — Medicare-approved approximately $2,500 to $5,000 per infusion. Your 20% coinsurance — approximately $500 to $1,000 per infusion. Annual coinsurance — approximately $8,700 to $17,400 without supplement.
With Medigap Plan G — bevacizumab costs $0 after the $257 annual deductible — saving $8,700 to $17,400 per year. Does Medicare cover ovarian cancer bevacizumab generously through Plan G — absolutely yes.
Does Medicare Cover PARP Inhibitors for Ovarian Cancer?
Does Medicare cover PARP inhibitors for ovarian cancer in 2026? Yes — Medicare Part D covers all FDA-approved PARP inhibitors for ovarian cancer — and the $2,000 annual Part D maximum is critically important for these extremely expensive oral agents.
PARP Inhibitors — Part D
All three FDA-approved PARP inhibitors for ovarian cancer are covered under Medicare Part D:
Olaparib (Lynparza) — covered Part D:
- FDA-approved for BRCA-mutant advanced ovarian cancer first-line maintenance
- FDA-approved for HRD-positive ovarian cancer maintenance in combination with bevacizumab
- Retail cost approximately $15,000 to $18,000 per month
- $2,000 annual Part D maximum — saves approximately $178,000 to $214,000 per year
Niraparib (Zejula) — covered Part D:
- FDA-approved for first-line maintenance regardless of BRCA status
- Retail cost approximately $12,000 to $15,000 per month
- $2,000 annual Part D maximum — saves approximately $142,000 to $178,000 per year
Rucaparib (Rubraca) — covered Part D:
- FDA-approved for BRCA-mutant recurrent ovarian cancer
- Retail cost approximately $12,000 to $15,000 per month
- $2,000 annual Part D maximum — critical protection
The $2,000 Part D Cap — Most Important PARP Inhibitor Protection
For ovarian cancer patients taking PARP inhibitors the $2,000 annual Part D out-of-pocket maximum is arguably the single most financially important Medicare benefit. At retail prices of $12,000 to $18,000 per month PARP inhibitors would cost $144,000 to $216,000 per year without insurance. The $2,000 annual cap means ovarian cancer patients on PARP inhibitor maintenance pay at most $2,000 per year — saving $142,000 to $214,000 annually.
Does Medicare Cover Targeted Therapy for Ovarian Cancer?
Does Medicare cover other targeted therapies for ovarian cancer in 2026? Yes — Medicare covers emerging targeted therapies for ovarian cancer.
Mirvetuximab Soravtansine (Elahere) — Part B
Mirvetuximab soravtansine — an antibody-drug conjugate targeting folate receptor alpha — for platinum-resistant ovarian cancer — covered Part B at 80% after deductible.
Combination PARP Plus Antiangiogenic — Covered
Olaparib plus bevacizumab combination maintenance — Lynparza covered Part D and bevacizumab covered Part B — Medicare covers both components through their respective pathways.
Does Medicare Cover Radiation Therapy for Ovarian Cancer?
Does Medicare cover radiation therapy for ovarian cancer in 2026? Radiation therapy is less commonly used for primary ovarian cancer treatment but Medicare covers it when medically appropriate.
Palliative Radiation — Covered
Palliative radiation for symptom relief — bone metastases, pelvic pain, bleeding — covered at 80% after deductible.
Stereotactic Radiosurgery — Covered
For isolated ovarian cancer metastases amenable to radiosurgery — covered.
With Medigap Plan G — all radiation therapy costs $0 after the annual deductible.
How Much Does Ovarian Cancer Treatment Cost with Medicare in 2026?
CA-125 and Lab Monitoring
CA-125 every 3 months — $0 — covered as diagnostic laboratory HE4 and other markers — $0
Surgery
Primary debulking inpatient — approximately $2,000 to $4,000 without supplement (Part A deductible plus surgeon) With Medigap Plan G — $0 after annual deductible
IV Chemotherapy
Carboplatin paclitaxel per cycle — approximately $400 to $800 your 20% 6 cycles total — approximately $2,400 to $4,800 your 20% With Medigap Plan G — $0 after annual deductible
Bevacizumab
Annual coinsurance — approximately $8,700 to $17,400 your 20% With Medigap Plan G — $0 after annual deductible — saves $8,700 to $17,400
PARP Inhibitors Part D
Lynparza Zejula Rubraca — $2,000 annual Part D maximum Annual savings — $142,000 to $214,000 at retail prices
Does Medicare Advantage Cover Ovarian Cancer?
Does Medicare Advantage cover ovarian cancer treatment in 2026? Yes — all Medicare Advantage plans must cover ovarian cancer treatment.
Prior authorization — required for PARP inhibitors, bevacizumab, and surgery on most plans. In-network gynecologic oncologist and facility — verify before scheduling. Annual maximum $9,350 — ovarian cancer patients reach this quickly. Part D $2,000 maximum — same critical protection for PARP inhibitors.
Frequently Asked Questions — Does Medicare Cover Ovarian Cancer
Does Medicare cover ovarian cancer treatment in 2026?
Yes — does Medicare cover ovarian cancer comprehensively in 2026 including surgery and debulking, carboplatin paclitaxel chemotherapy at 80%, bevacizumab at 80%, CA-125 monitoring at $0, BRCA testing, and PARP inhibitors including Lynparza Zejula and Rubraca under Part D with $2,000 annual maximum. With Medigap Plan G most ovarian cancer treatment costs $0 after the annual deductible.
Does Medicare cover PARP inhibitors for ovarian cancer?
Yes — Medicare Part D covers olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca) for ovarian cancer. The $2,000 annual Part D maximum limits patient costs to $2,000 per year regardless of retail price — saving ovarian cancer patients $142,000 to $214,000 annually compared to paying retail prices.
Does Medicare cover Avastin bevacizumab for ovarian cancer?
Yes — Medicare Part B covers bevacizumab (Avastin) for ovarian cancer at 80% after the $257 annual deductible. Annual bevacizumab coinsurance can reach $8,700 to $17,400 without a supplement. With Medigap Plan G bevacizumab costs $0 after the annual deductible.
Does Medicare cover CA-125 testing for ovarian cancer?
Yes — Medicare covers CA-125 blood tests at $0 as diagnostic laboratory services when medically ordered. For ovarian cancer survivors requiring quarterly CA-125 monitoring the $0 coverage provides significant ongoing savings.
Does Medicare cover BRCA testing for ovarian cancer?
Yes — Medicare covers BRCA1 and BRCA2 genetic testing for women diagnosed with ovarian cancer at 80% after the deductible. BRCA status determines eligibility for FDA-approved PARP inhibitor maintenance therapy — making this testing critically important for ovarian cancer patients.
Summary — Does Medicare Cover Ovarian Cancer 2026
Does Medicare cover ovarian cancer treatment in 2026? Yes — Medicare provides comprehensive ovarian cancer coverage from CA-125 monitoring at $0 through debulking surgery, platinum-based chemotherapy, bevacizumab, and PARP inhibitor maintenance therapy. The financial protections are extraordinary — the $2,000 Part D cap on PARP inhibitors saves $142,000 to $214,000 annually and Medigap Plan G eliminates bevacizumab coinsurance potentially saving $8,700 to $17,400 per year.
For ovarian cancer patients taking PARP inhibitor maintenance therapy the $2,000 annual Part D maximum is arguably the most financially significant Medicare drug benefit for any single condition — providing protection from medications that would otherwise cost $144,000 to $216,000 per year at retail prices. Ovarian cancer patients represent one of the groups that benefit most dramatically from comprehensive Medicare drug coverage.
For free help understanding your Medicare ovarian cancer coverage contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org or call Medicare free at 1-800-633-4227.
This guide is for informational purposes only. Always consult your gynecologic oncologist and verify current Medicare coverage at Medicare.gov.
Sources: Medicare.gov | CMS.gov | SSA.gov | AARP.org
Last updated: April 2026 | Author: James Carter, Independent Medicare Research Analyst
